The importance of pharma CSRThe industry is increasingly aware of the importance of corporate social responsibility (CSR) programmes – and Alex Kalomparis, Share XThe importance of pharma CSRhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-importance-of-pharma-csr/
ViiV hails data showing switch from Truvada to two-drug HIV regimenViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors Share XViiV hails data showing switch from Truvada to two-drug HIV regimenhttps://pharmaphorum.com/news/viiv-hails-data-showing-switch-from-truvada-to-two-drug-hiv-regimen/
ViiV’s Dovato HIV pill approved in EUViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over Share XViiV’s Dovato HIV pill approved in EUhttps://pharmaphorum.com/news/viivs-dovato-hiv-pill-approved-in-eu/
Addressing global health challenges: the pharmaphorum podcastFor episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to Share XAddressing global health challenges: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/iavi-global-health-challenges/
Gilead faces lawsuit over HIV drug pricingGilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving Share XGilead faces lawsuit over HIV drug pricinghttps://pharmaphorum.com/news/gilead-faces-lawsuit-over-hiv-drug-pricing/
Gilead to donate HIV drug to US government prophylaxis schemeGilead has announced it will donate its HIV drug Truvada to a US-government led prophylaxis programme to end Share XGilead to donate HIV drug to US government prophylaxis schemehttps://pharmaphorum.com/news/gilead-to-donate-hiv-drug-to-us-government-prophylaxis-scheme/
ViiV files patient-friendly monthly HIV injection in USViiV Healthcare has submitted its once-monthly two-drug injected treatment for HIV to the US Food and Drug Administration Share XViiV files patient-friendly monthly HIV injection in UShttps://pharmaphorum.com/news/viiv-files-patient-friendly-monthly-hiv-injection-in-us/
Antibody suppresses HIV for four monthsA new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the Share XAntibody suppresses HIV for four monthshttps://pharmaphorum.com/news/antibody-suppresses-hiv-for-four-months/
ViiV hopes for blockbuster with HIV drug combo approvalThe FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for Share XViiV hopes for blockbuster with HIV drug combo approvalhttps://pharmaphorum.com/news/viiv-hopes-blockbuster-hiv-drug-combo-approval/
